KemPharm (KMPH) Gets a Buy Rating from Canaccord Genuity


Canaccord Genuity analyst Dewey Steadman maintained a Buy rating on KemPharm (NASDAQ: KMPH) today and set a price target of $11. The company’s shares opened today at $4.80.

According to TipRanks.com, Steadman is a 3-star analyst with an average return of 3.3% and a 38.3% success rate. Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Pacira Pharmaceuticals, and Perrigo Company plc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for KemPharm with a $12.13 average price target, a 152.7% upside from current levels. In a report issued on August 9, Oppenheimer also assigned a Buy rating to the stock with a $13 price target.

.

See today’s analyst top recommended stocks >>

Based on KemPharm’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9.99 million. In comparison, last year the company had a GAAP net loss of $6.52 million.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KMPH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts